Leadership Overview
Revance Therapeutics has 5 executives leading key functions including strategy, technology, human resources, revenue, and legal affairs.
Focused on advancing biotechnology innovation, Revance Therapeutics delivers novel botulinum toxin products to address aesthetic and therapeutic needs while maintaining a commitment to clinical excellence and market expansion.
Focused on advancing biotechnology innovation, Revance Therapeutics delivers novel botulinum toxin products to address aesthetic and therapeutic needs while maintaining a commitment to clinical excellence and market expansion.
Leadership Roles at Revance Therapeutics
Nadeem Moiz - Chief Executive Officer
Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Overseeing the development and commercialization of novel botulinum toxin products, the Chief Executive Officer ensures alignment between clinical trial progress and market readiness. This leadership role involves managing complex stakeholder relationships and driving the organization toward sustainable growth within the competitive aesthetic and therapeutic sectors. By prioritizing operational efficiency and scientific innovation, Moiz secures the company's position as a leader in the pharmaceutical landscape. The Chief Executive Officer maintains rigorous oversight of the entire product pipeline, from early-stage research to final commercial deployment. Through strategic resource allocation and executive decision-making, Nadeem Moiz fosters a culture of excellence that supports the advancement of DaxibotulinumtoxinA for various medical and cosmetic indications across global markets.
Satish Kalala - Chief Technology Officer
Satish Kalala, the Chief Technology Officer at Revance Therapeutics, architects the digital infrastructure and technical frameworks necessary to support advanced pharmaceutical manufacturing. Overseeing the integration of data-driven systems, the Chief Technology Officer ensures that research and development processes remain efficient and compliant with industry standards. This leadership role involves implementing cutting-edge technological solutions to accelerate the clinical trial phases for DaxibotulinumtoxinA. By optimizing internal workflows and data management, Kalala directly impacts the speed and accuracy of product development cycles. The Chief Technology Officer collaborates with scientific teams to leverage emerging technologies that enhance the efficacy of topical gel formulations and injectable treatments. Satish Kalala drives the digital transformation of the company, ensuring that technical capabilities remain at the forefront of the biotechnology industry while supporting the broader mission of delivering high-quality therapeutic solutions to patients worldwide.
Matthew Argano - Chief Human Resources Officer
Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, directs the talent acquisition and organizational development strategies essential for a high-growth biotechnology environment. Overseeing the cultivation of a specialized workforce, the Chief Human Resources Officer ensures that the company attracts and retains top-tier scientific and commercial talent. This leadership role involves designing comprehensive performance management systems and fostering an inclusive corporate culture that aligns with the mission of advancing medical innovation. By implementing strategic workforce planning, Argano supports the operational needs of the clinical and manufacturing teams. The Chief Human Resources Officer manages internal communications and professional development programs to maintain high levels of employee engagement and productivity. Matthew Argano drives the organizational structure required to scale operations effectively, ensuring that the human capital strategy remains synchronized with the company's long-term objectives in the aesthetic and therapeutic markets.
Steven Kreider - Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics
Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, directs the commercialization strategies and revenue growth initiatives for the company's diverse product portfolio. Overseeing the expansion of market presence, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics ensures that aesthetic and therapeutic solutions reach target providers and patients effectively. This leadership role involves managing sales operations and developing strategic partnerships to maximize the market penetration of DaxibotulinumtoxinA. By analyzing market trends and competitive dynamics, Kreider optimizes pricing and distribution models to drive financial performance. The Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics collaborates with marketing and clinical teams to ensure consistent messaging and product adoption. Steven Kreider secures the company's revenue streams by executing robust commercial plans that address the specific needs of the aesthetic and therapeutic sectors across North American markets.
Kira Schwartz - Chief Legal Officer
Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, directs the legal and regulatory affairs that govern the development and commercialization of novel pharmaceutical products. Overseeing intellectual property protection and compliance with clinical trial regulations, the Chief Legal Officer ensures that the company operates within the complex legal frameworks of the biotechnology industry. This leadership role involves managing risk, negotiating strategic agreements, and providing counsel on corporate governance matters. By safeguarding the company's proprietary technology and navigating regulatory hurdles, Schwartz facilitates the smooth progression of drug candidates through clinical phases. The Chief Legal Officer collaborates with executive leadership to ensure that all business activities align with legal requirements and ethical standards. Kira Schwartz drives the legal strategy that protects the company's innovations, ensuring that the organization maintains a strong competitive advantage while adhering to the highest standards of corporate integrity and regulatory compliance.
Explore Leadership Teams in Manufacturing
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes medicines for serious diseases with significant unmet medical needs. Its portfolio includes therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also advances research programs in kidney disease, type 1 diabetes, myotonic dystrophy, and other genetic disorders, serving patients through healthcare providers, specialty pharmacies, hospitals, and distributors worldwide.
Company Leadership GL
AL
OG
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership IC
HA
NM
BS
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.
Company Leadership TI
RN
FA
TriRx Pharmaceuticals is a contract development and manufacturing organization specializing in both non-sterile and sterile products, including animal health injectables and packaging solutions. The company offers a wide range of capabilities such as development and analytics, sterile and non-sterile manufacturing, and packaging services. With facilities located in Huntsville, Alabama, and Segré, France, TriRx aims to support customers' commercialization efforts across global markets. Their target clients include pharmaceutical companies looking for advanced solutions to bring their products to market.
Company Leadership TT
JS
KL
RM
Frequently Asked Questions Regarding Revance Therapeutics Top Executives and Leadership Team
